Shawn Ryan Eichelberger

US Patent:

7968543, Jun 28, 2011

Filed:

Nov 7, 2008

Appl. No.:

12/267321

Inventors:

Joyce K. James - San Diego CA, US
Traci L. Savall - San Diego CA, US
Shawn R. Eichelberger - San Diego CA, US

Assignee:

Ambit Biosciences Corporation - San Diego CA

International Classification:

A61K 31/535
A61K 31/41
A61K 31/42

US Classification:

5142315, 514360, 514380

Abstract:

Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Further, pharmaceutical formulations are provided. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.